Drugs / SULCARDINE
SULCARDINE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04650542 | Feb → Aug 2021 | — | HUYABIO International, LLC. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04680026 | Jun 2021 → Dec 2025 overdue | atrial fibrillation | HUYABIO International, LLC. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03397641 Comparator | Oct 2017 → Jul 2018 | atrial fibrillation | HUYABIO International, LLC. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SULCARDINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3638051 ↗ |
| Known as | HBI-3000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04680026 ↗ |
| Known as | SULCARDINE SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3638051 ↗ |
| Known as | Sulcardine sulfate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL3638051 ↗ |
| Action | Inhibit | “Small molecule, multi-ion channel blocker” NCT03397641 ↗ |
| Modality | Small molecule | “Small molecule, multi-ion channel blocker” NCT03397641 ↗ |
| Route | Intravenous | “intravenous infusion” NCT03397641 ↗ |